Pozen Inc. (NASDAQ:POZN) shares fell 8.36% to $11.07 in early afternoon trading ahead of a decision from the FDA regarding an arthritis medication.
The FDA will issue a decision on whether to approve its new arthritis medication Vimovo by the end of Friday.
The drug was co-developed with AstraZeneca (NYSE:AZN). AstraZeneca shares are trading 0.50% lower at $44.12.
Link to this comment:
All Comments (0)